Effectiveness And Cost-Effectiveness Of HPV Vaccination And HPV-Based Cervical Cancer Screening Strategies In China
Funder
National Health and Medical Research Council
Funding Amount
$420,692.00
Summary
In the absence of preventative initiatives, up to 187,000 women will develop cervical cancer in China every year. However, the disease is preventable using human papillomavirus (HPV) vaccination and primary HPV screening. Building on previous work, we will evaluate the most effective and cost-effective options for cervical cancer prevention, in order to provide an comprehensive evidence base for China’s health decision-makers.
Centre For Research Excellence In Cervical Cancer Control (C4)
Funder
National Health and Medical Research Council
Funding Amount
$2,486,383.00
Summary
Cervical cancer remains common globally despite over 50 years of Pap testing. Australia led the world in HPV vaccination and in 2017 will be the first to deliver a national screening program based on HPV testing. Our CRE, led by cervical cancer prevention experts at CCNSW,VCS, and Kirby, will marry cross-disciplinary research and evaluation of HPV vaccination and screening to provide solid evidence about these new approaches with a view to ultimately reducing the global burden of this cancer.
Point-of-care HPV-DNA Testing For Cervical Cancer Screening In High-burden, Low-resource Settings
Funder
National Health and Medical Research Council
Funding Amount
$891,184.00
Summary
We will undertake the first field evaluation of a novel, newly-available, easy to use, and highly accurate point-of-care (POC) test for high-risk human papillomavirus (hrHPV) infection that will allow trained health staff to identify women at increased risk of cervical cancer and to provide same-day cervical cryotherapy for pre-cancer lesions identified on clinical examination.
An Epidemic Of Vulvar Cancer In Young Women: Investigating The Role Of Human Papillomavirus And Genetic Susceptibility
Funder
National Health and Medical Research Council
Funding Amount
$489,706.00
Summary
Vulvar cancer is a rare disease; in 1993-1997 the age-adjusted incidence rate in Australia was 1.4 per 100,000 women (average 207 cases per year), similar to the incidence in most other countries. An epidemic of cases of vulvar cancer has been identified in younger Indigenous women living in remote communities in the Northern Territory (NT). Vulvar cancer is over fifty times more common in women aged less than 50 years in these communities than in the total Australian population. Women in these ....Vulvar cancer is a rare disease; in 1993-1997 the age-adjusted incidence rate in Australia was 1.4 per 100,000 women (average 207 cases per year), similar to the incidence in most other countries. An epidemic of cases of vulvar cancer has been identified in younger Indigenous women living in remote communities in the Northern Territory (NT). Vulvar cancer is over fifty times more common in women aged less than 50 years in these communities than in the total Australian population. Women in these communities also experience higher rates of high-grade Vulvar Intraepithelial Neoplasia (a pre-cursor to vulvar cancer), than elsewhere in the NT. Vulvar cancer is usually much more common in older women than younger women. In young women vulvar cancer and VIN are thought to be caused by infection with cancer causing strains of human papillomavirus (HPV), particularly the strain known as HPV16. In older women, vulvar cancer is not caused by HPV. In the remote communities in the NT, vulvar cancer is occurring almost entirely in young women, the amount of cancer occurring in older women in these communities is similar to the amount expected in the total Australian population. This project will investigate the cause of this epidemic of vulvar cancer and high-grade VIN. It will investigate whether HPV16 is more prevalent in these communities than elsewhere in Australia; whether there is a variant strain of HPV16 in these communites that is more virulent at causing cancer, and whether the disease occurs more commonly in families, which would mean that women in these communities inherit an increased susceptibility to vulvar cancer and VIN. This project will help to increase our understanding of vulvar cancer and VIN, help to control this epidemic, and inform whether the new HPV vaccines may be effective in preventing vulvar cancer in these communities.Read moreRead less
Effectiveness And Cost-effectiveness Of Systematic Screening For Lynch Syndrome (LS) In Australia
Funder
National Health and Medical Research Council
Funding Amount
$485,762.00
Summary
Lynch syndrome (LS) is an inherited condition that puts people at an increased risk of developing a range of cancers. We will use a detailed simulation model to evaluate the potential health benefits of testing new cases of colorectal, endometrial and ovarian cancers for LS, and whether this would be cost-effective. The aim is to identify LS-related cancer cases, so family members can be offered LS testing, and individuals found to have LS can be offered close observation/preventative surgery.
Assessment Of The Effects Of Pathogenic Germline TP53 Mutations; International Sarcoma Kindred Study Participants’ Views Of Feedback Of Genetic Research Results And The Acceptability Of Taking Part In A Pilot Screening Programme
Funder
National Health and Medical Research Council
Funding Amount
$55,242.00
Summary
The International Sarcoma Kindred Study (ISKS) aims to identify individuals who harbour germline TP53 mutations. TP53 mutations are characterised by the development of multiple cancers including sarcoma. This project will assess ISKS participants’ views of the feedback of genetic research information and will develop sensitive feedback practices. The acceptability and psychological impact of taking part in a pilot screening protocol designed for cancer-prone populations will also be assessed.
Re-participation In Screening For Colorectal Cancer: Behavioural Outcomes And Predictors.
Funder
National Health and Medical Research Council
Funding Amount
$687,438.00
Summary
Screening for bowel cancer (CRC) is an important public health initiative. It is most effective when undertaken regularly but there is little research on what personal factors relate to ongoing participation in a screening program. This study will determine the factors associated with ongoing participation in CRC screening and will lead to better screening programs and improved health benefits. This study directly addresses the Cancer Australia priority area re improving screening programs.
Green Tea Polyphenols And Cancer Prevention: Use Of Population Controls And Biomarkers To Elicit Causal Pathways
Funder
National Health and Medical Research Council
Funding Amount
$956,189.00
Summary
There is laboratory evidence that chemicals in green tea (poloyphenols) protect against cancer. Epidemiologic studies in humans have generally supported these findings, especially for breast cancer. This project is a crucial stepping stone towards future prospects of a large-scale trial using green tea extract. It will see if the protection extends to leukaemia and bowel cancer, and will identify the genetic makeup of people who are able to benefit the most from green tea polyphenols.
The Australian And New Zealand Diabetes And Cancer Collaboration
Funder
National Health and Medical Research Council
Funding Amount
$412,291.00
Summary
Diabetes, obesity, metabolic syndrome, hypertension and cancer are chronic diseases faced by many Australians. There is some evidence to suggest that those with diabetes or are obese are at an increased risk of cancer. Sufficiently large studies to examine these relationships do not exist in Australia. This project aims to pool Australian and New Zealand longitudinal studies which have information on diabetes and obesity to examine the relationship between diabetes, obesity and cancer.